share_log

Clearmind Medicine | SC 13G: Statement of acquisition of beneficial ownership by individuals-Richard Abbe(9.99%),Iroquois Capital Management L.L.C.(7.51%), etc.

Clearmind Medicine | SC 13G：超過5%持股股東披露文件-Richard Abbe(9.99%),Iroquois Capital Management L.L.C.(7.51%)等

美股sec公告 ·  01/22 13:00
牛牛AI助理已提取核心訊息
On January 11, 2024, Clearmind Medicine Inc, a biopharmaceutical company, was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by notable investors. Iroquois Capital Management L.L.C., along with individuals Richard Abbe and Kimberly Page, reported shared voting and dispositive power over 125,000 shares of Clearmind Medicine's common stock and warrants to purchase an additional 157,952 shares. Separately, Richard Abbe reported sole voting and dispositive power over 187,500 shares and warrants for 189,847 shares, while Kimberly Page reported shared power over the same number of shares and warrants as Iroquois. The filings indicate that the investors collectively hold a substantial percentage of the company's shares, with Abbe's holdings representing 9.99% and Iroquois and Page's holdings...Show More
On January 11, 2024, Clearmind Medicine Inc, a biopharmaceutical company, was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by notable investors. Iroquois Capital Management L.L.C., along with individuals Richard Abbe and Kimberly Page, reported shared voting and dispositive power over 125,000 shares of Clearmind Medicine's common stock and warrants to purchase an additional 157,952 shares. Separately, Richard Abbe reported sole voting and dispositive power over 187,500 shares and warrants for 189,847 shares, while Kimberly Page reported shared power over the same number of shares and warrants as Iroquois. The filings indicate that the investors collectively hold a substantial percentage of the company's shares, with Abbe's holdings representing 9.99% and Iroquois and Page's holdings each representing 7.51% of the class. The warrants are subject to ownership limitations, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding shares, except for certain warrants with a 4.99% blocker. The reporting persons have entered into a Joint Filing Agreement, and the filings were completed on January 22, 2024.
2024年1月11日，生物製藥公司Clearmind Medicine Inc成爲向美國證券交易委員會提交的附表13G文件的主體，這表明著名投資者對股票進行了重大收購。易洛魁資本管理有限責任公司以及個人理查德·阿貝和金伯利·佩奇報告了對Clearmind Medicine12.5萬股普通股和額外購買157,952股股票的認股權證的共同投票權和處置權。另外，理查德·阿貝報告了對187,500股股票和189,847股認股權證的唯一投票權和處置權，而金伯利·佩奇則報告了對與易洛魁相同數量的股票和認股權證的共享權力。文件顯示，投資者共同持有該公司很大一部分股份，阿貝的持股量佔該類別的9.99％，易洛魁和佩奇的持股量各佔該類別的7.51％。認股權證受所有權限制，如果認股權證會導致所有權超過已發行股份的9.99％，則無法行使認股權證，但某些封鎖率爲4.99％的認股權證除外。申報人已簽訂聯合申報協議，申報於2024年1月22日完成。
2024年1月11日，生物製藥公司Clearmind Medicine Inc成爲向美國證券交易委員會提交的附表13G文件的主體，這表明著名投資者對股票進行了重大收購。易洛魁資本管理有限責任公司以及個人理查德·阿貝和金伯利·佩奇報告了對Clearmind Medicine12.5萬股普通股和額外購買157,952股股票的認股權證的共同投票權和處置權。另外，理查德·阿貝報告了對187,500股股票和189,847股認股權證的唯一投票權和處置權，而金伯利·佩奇則報告了對與易洛魁相同數量的股票和認股權證的共享權力。文件顯示，投資者共同持有該公司很大一部分股份，阿貝的持股量佔該類別的9.99％，易洛魁和佩奇的持股量各佔該類別的7.51％。認股權證受所有權限制，如果認股權證會導致所有權超過已發行股份的9.99％，則無法行使認股權證，但某些封鎖率爲4.99％的認股權證除外。申報人已簽訂聯合申報協議，申報於2024年1月22日完成。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。